ProMIS Neurosciences is trading 5.44% higher at $9.74, with no clear company-specific catalyst identified. - No company-specific announcement dated October 9 was identified; the latest release on the company’s site was the October 6 appointment of Ivana Rubino as chief commercial officer. - The biotech sector is up 2.50%, while major indexes are up less than 0.5%. - No trading volume or activity details are available in the supplied price context, leaving the additional move unexplained.